Dupixent® (dupilumab) approved in china as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (copd)

Approval follows eu approval of dupixent for adults with copd with raised blood eosinophils, and is based on two landmark phase 3 trials showing dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
REGN Ratings Summary
REGN Quant Ranking